Benzinga | Aug 10, 2021 07:31AM EDT

Wells Fargo Downgrades bluebird bio to Equal-Weight, Lowers Price Target to $25

Wells Fargo analyst Yanan Zhu downgrades bluebird bio (NASDAQ:BLUE) from Overweight to Equal-Weight and lowers the price target from $60 to $25.